#Japan #Allergan #Minato-ku #Aesthetics #Botulinum Toxin

Allergan Aesthetics Pursues New Approval

Allergan Aesthetics, a subsidiary of AbbVie headquartered in Minato-ku, Tokyo, has announced the submission of an application for the additional indication of botulinum toxin type A for treating masseter hypertrophy in adults in Japan. This application is based on data derived from a domestic phase III clinical trial conducted with Japanese adult patients.

Masseter hypertrophy, a condition where the masseter muscles become enlarged, can lead to aesthetic concerns regarding the lower face. Beyond physical appearance, it may also impose psychological burdens and affect social activities, subsequently impacting the overall quality of life (QOL).

Masseter muscles play a vital role in chewing, and hypertrophy can occur due to certain lifestyle habits, such as grinding teeth or chewing hard foods. Studies suggest that this condition is most prevalent among individuals in their 20s and 30s. The enlargement of these muscles can create a broader, more angular appearance of the lower face, leading to dissatisfaction and diminished self-esteem. Additionally, this physical change can adversely affect interpersonal relationships and limit career opportunities due to social anxiety.

Historically, treatment options for masseter hypertrophy included conservative approaches, such as modifications in lifestyle and diet or more invasive surgical interventions like bone resection. However, surgical options come with risks and the burden of recovery, highlighting the need for less invasive alternatives.

The new approval application aims to provide a non-surgical solution to enhance patient QOL by using botulinum toxin injections. This intervention works because the botulinum toxin binds to receptors in motor nerves, inhibiting the release of acetylcholine and blocking cholinergic nerve transmission, ultimately leading to localized muscle relaxation. The injections create a temporary chemical denervation effect, resulting in reduced muscle activity over time. As neural function gradually recovers, the muscle's original strength returns.

Allergan Aesthetics, known for its commitment to advancing aesthetic medicine, aims to expand treatment options that contribute to improved QOL for patients. The company develops and manufactures a diverse range of products in the aesthetic field, including botulinum treatments, hyaluronic acid injectables, cryolipolysis for localized fat reduction, and breast reconstruction-related products. Their dedication to innovation, education, and excellent service aligns with the evolving needs of its customers.

For more details on Allergan Aesthetics, visit www.allerganaesthetics.jp, or follow them on Instagram and other beauty information sites at www.allerganbeauty.jp.

About AbbVie

AbbVie is focused on developing innovative pharmaceutical solutions to address critical health challenges. The company aims to enrich lives by tackling complex medical issues across various domains, including immunology, oncology, neuroscience, eye care, and aesthetic medicine through the Allergan Aesthetics portfolio. For more information about AbbVie, visit www.abbvie.com and stay connected on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.

In Japan, AbbVie concentrates on developing and providing products specifically in immunology, liver disease, neuroscience, oncology, eye care, and their Allergan Aesthetics portfolio. To learn more about AbbVie in Japan, visit www.abbvie.co.jp, where you can also find more content on Facebook and YouTube.